Systemic Lupus Erythematosus Clinical Trials in Beijing, Beijing Municipality
16 recruitingBeijing, Beijing Municipality, China
Showing 1–16 of 16 trials
Recruiting
Phase 2
A Study of E6742 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Eisai Co., Ltd.256 enrolled17 locationsNCT07515014
Recruiting
Phase 2
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Hangzhou Sumgen Biotech Co., Ltd.120 enrolled1 locationNCT07447986
Recruiting
Phase 3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
AbbVie1,000 enrolled369 locationsNCT05843643
Recruiting
Phase 1Phase 2
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Beijing GoBroad Hospital18 enrolled1 locationNCT06585514
Recruiting
Phase 1
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)
Beijing GoBroad Hospital27 enrolled1 locationNCT06822881
Recruiting
Phase 1Phase 2
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Excyte Biopharma Ltd189 enrolled1 locationNCT07010835
Recruiting
Phase 1Phase 2
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
Systemic Lupus Erythematosus (SLE)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.198 enrolled1 locationNCT07185269
Recruiting
Not Applicable
IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)
Refractory Systemic Lupus Erythematosus
Peking University Third Hospital6 enrolled1 locationNCT06513429
Recruiting
Phase 2
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Zenas BioPharma (USA), LLC190 enrolled82 locationsNCT06559163
Recruiting
Phase 1
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Inflammatory Myopathy+5 more
China Immunotech (Beijing) Biotechnology Co., Ltd.12 enrolled1 locationNCT06978647
Recruiting
Long-Term Outcomes in SLE at Peking University People's Hospital
Systemic Lupus Erythematosus
Peking University People's Hospital1,000 enrolled1 locationNCT07005479
Recruiting
Phase 2
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Systemic Lupus ErythematosusSjogren SyndromeInflammatory Myopathy+6 more
Peking University People's Hospital50 enrolled1 locationNCT06794008
Recruiting
Phase 1Phase 2
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Systemic Lupus ErythematosusSjogren's SyndromeAutoimmune Diseases+1 more
Essen Biotech60 enrolled1 locationNCT06428188
Recruiting
Phase 1Phase 2
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Systemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSjogren's Syndrome+6 more
Essen Biotech75 enrolled1 locationNCT06350110
Recruiting
Phase 3
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Liu Tian60 enrolled1 locationNCT05339217
Recruiting
Phase 4
Anti-CD20 Antibodies for Treatment of SLE-PAH
Pulmonary Arterial HypertensionSystemic Lupus Erythematosus
Chinese SLE Treatment And Research Group50 enrolled1 locationNCT05828147